Subsequent in vitro and in vivo studies have indicated that PDK4 plays a role in mediating DLBCL’s resistance to rituximab by downregulating CD20 expression [8] despite the several benefits of targeted therapy using small interfering RNA (siRNA), challenges such as siRNA’s short half-life, poor membrane penetration, rapid degradation in circulation, and low stability persist [9]. The gene discussed is PDK4; the disease is diffuse large B-cell lymphoma.